Fatal pulmonary embolism following antipsychotic treatment and physical restraint.
Hewer
W
W
Kauder
E
E
Vierling
P
P
D000368:Aged; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001569:Benzodiazepines / Q000009:adverse effects* / Q000627:therapeutic use; D017809:Fatal Outcome; D005260:Female; D006220:Haloperidol / Q000009:adverse effects* / Q000627:therapeutic use; D006323:Heart Arrest / Q000209:etiology; D006333:Heart Failure / Q000209:etiology; D006801:Humans; D006993:Hypnotics and Sedatives / Q000009:adverse effects / Q000627:therapeutic use; D008140:Lorazepam / Q000009:adverse effects / Q000494:pharmacology; D000077152:Olanzapine; D017410:Practice Guidelines as Topic; D011651:Pulmonary Artery / Q000473:pathology; D011655:Pulmonary Embolism / Q000209:etiology* / Q000473:pathology / Q000517:prevention & control; D012149:Restraint, Physical / Q000009:adverse effects*; D012563:Schizophrenia, Paranoid / Q000188:drug therapy / Q000628:therapy; D054556:Venous Thromboembolism / Q000209:etiology / Q000517:prevention & control
D014150:Antipsychotic Agents; D006993:Hypnotics and Sedatives; D001569:Benzodiazepines; D006220:Haloperidol; D000077152:Olanzapine; D008140:Lorazepam